Populist administrative overhauls dismantle emergency-use frameworks in favor of alternative therapies and radical disclosure.
New regulatory leadership leverages proactive document releases and the wind-down of emergency declarations to divert focus from standard pharmaceutical paths toward alternative approvals.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA is moving to codify a policy of proactive CRL publication, advancing a controversial agenda of radical disclosure over long-standing corporate confidentiality.
Under new administrative priorities, the advisory committee overrode career scientists to recommend adding alternative therapies like peptides to bulk compounding lists.
New populist leadership at HHS is dismantling emergency-use frameworks by ending remaining COVID-19 EUA declarations.